Streetbeat News

Products Services

NOWVF

NowVertical Group Inc. has announced the release of a new AI Financial Agent as part of an update to its NowHub-Finance solution, enhancing its AI-driven data solutions for finance teams.

Portfolio Pulse from

December 17, 2024 | 1:15 pm

LICN

Lichen China Limited (NASDAQ: LICN) is set to launch its AI large-scale model, co-developed with JD Technology, for trial operation by the end of December. This follows a cooperation agreement signed in October 2024.

Portfolio Pulse from

December 17, 2024 | 1:15 pm

SNAL

Snail, Inc. (Nasdaq: SNAL) has partnered with Loric Games to acquire publishing rights for the game Echoes of Elysium, an airship survival RPG.

Portfolio Pulse from

December 17, 2024 | 1:15 pm

NXPI

NXP Semiconductors (NASDAQ: NXPI) is set to acquire Aviva Links for $242.5 million, enhancing its capabilities in automotive networking and connectivity solutions.

Portfolio Pulse from

December 17, 2024 | 1:15 pm

AVAI

Avant Technologies Inc. and Ainnova Tech have secured exclusive rights to advanced AI algorithms for early detection of four additional diseases, enhancing their healthcare technology offerings.

Portfolio Pulse from

December 17, 2024 | 1:15 pm

SEED

Origin Agritech Ltd. (NASDAQ: SEED) held its 2025 R&D and Business Management Conference in Beijing, showcasing its leadership in agricultural technology.

Portfolio Pulse from

December 17, 2024 | 1:15 pm

SLVDF

Silver Dollar Resources Inc. has identified two new IP anomalies at its Ranger-Page Project in Idaho's Silver Valley. The project benefits from excellent infrastructure and a skilled workforce, with ongoing drilling activities.

Portfolio Pulse from

December 17, 2024 | 1:15 pm

WHG

WEBs Investments Inc. and Westwood Holdings Group have launched the Defined Volatility℠ ETF series, including DVSP and DVQQ, designed to offer stable investment experiences by adjusting equity exposure based on real-time volatility.

Portfolio Pulse from

December 17, 2024 | 1:15 pm

IMMP

Immutep Limited announced favorable initial safety data from its Phase I trial of IMP761, with no treatment-related adverse events reported in the first three of five dose cohorts.

Portfolio Pulse from

December 17, 2024 | 1:15 pm